The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
Official Title: Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma
Study ID: NCT00297258
Brief Summary: The purpose of this study is to evaluate the activity and tolerability of pazopanib in subjects with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies or for whom no standard therapy exists and to characterize the pharmacokinetics of pazopanib in this subject population.
Detailed Description:
Minimum Age: 21 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
GSK Investigational Site, Bruxelles, , Belgium
GSK Investigational Site, Leuven, , Belgium
GSK Investigational Site, Lyon cedex 03, , France
GSK Investigational Site, Marseille, , France
GSK Investigational Site, Paris Cedex 05, , France
GSK Investigational Site, Villejuif, , France
GSK Investigational Site, Budapest, , Hungary
GSK Investigational Site, Groningen, , Netherlands
GSK Investigational Site, Leiden, , Netherlands
GSK Investigational Site, Rotterdam, , Netherlands
GSK Investigational Site, Manchester, Lancashire, United Kingdom
GSK Investigational Site, Glasgow, , United Kingdom
GSK Investigational Site, Leeds, , United Kingdom
GSK Investigational Site, London, , United Kingdom
GSK Investigational Site, Newcastle upon Tyne, , United Kingdom
GSK Investigational Site, Sheffield, , United Kingdom
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR